TAK-632 - 10mM in DMSO, high purity , CAS No.1228591-30-7, Inhibitor of aurora kinase B;Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of fibroblast growth factor receptor 3;Inhibitor of platelet derived growth factor receptor beta;Inhibitor of Raf-1 proto-oncogene; serine/threonine kinase;I

Item Number

T420987

• Specifications & Purity: Moligand™, 10mM in DMSO
• Biochemical and Physiological Mechanisms: TAK-632 is a potent pan-Raf inhibitor with IC50 of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.
• Storage Temp: Store at -80°C
• Shipped In: Ice chest + Ice pads
• Grade: Moligand™
• Action Type: INHIBITOR
• Mechanism of action: Inhibitor of aurora kinase B;Inhibitor of B-Raf proto-oncogene; serine/threonine kinase;Inhibitor of fibroblast growth factor receptor 3;Inhibitor of platelet derived growth factor receptor beta;Inhibitor of Raf-1 proto-oncogene; serine/threonine kinase;I

Product Description

Information

TAK-632 is a potent pan-Rafinhibitor withIC50of 8.3 nM and 1.4 nM for B-Raf(wt) and C-Raf in cell-free assays, respectively, showing less or no inhibition against other tested kinases.

Targets

C-Raf (Cell-free assay); B-Raf (Cell-free assay); Aurora B (Cell-free assay); PDGFRβ (Cell-free assay); FGFR3 (Cell-free assay) 15112,1.4 nM; 8.3 nM; 66 nM ;120 nM; 280 nM

In vitro

TAK-632 inhibits phosphorylation of MEK and ERK in melanoma A375 cells (BRAFV600E) with IC50 of 12 nM and 16 nM, respectively. In human melanoma HMVII cells (NRASQ61K/BRAFG469V), TAK-632 also shows strong inhibition of pMEK and pERK with IC50 of 49 nM and 50 nM, respectively. Moreover, TAK-632 also exhibits antiproliferative activity in both A375 and HMVII cells with GI50 of 66 nM and 200 nM, respectively. TAK-632 induces RAF dimerization but inhibits the kinase activity of the RAF dimer because of its slow dissociation from RAF. The combination of TAK-632 and TAK-733 exhibits synergistic antiproliferative effects in BRAF- and NRAS-mutated melanoma cells.

In vivo

TAK-632 shows superior oral bioavailability in both rats and dogs. TAK-632 (3.9–24.1 mg/kg, p.o.) exhibits dose-dependent antitumor efficacy without severe body weight reduction in a melanoma A375 (BRAFV600E) xenograft model and a human melanoma HMVII (NRASQ61K/BRAFG469V) xenograft in rats. In NRAS-mutant melanoma SK-MEL-2 xenograft model, TAK-632 (60 or 120 mg/kg, p.o.) also exhibits potent antitumor efficacy without severe toxicity.

Cell Research(from reference)

Cell lines：A375 and HMVII cells 

Concentrations：~2 μM 

Incubation Time：72 hours